Publication | Open Access

Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells

Hematological MalignancyTyrosine-kinase Inhibitor IbrutinibMedicineMixed-phenotype Acute LeukemiaImmunologyHematologyImmune Checkpoint InhibitorMechanistic StudyOncologyCell BiologyPatient-derived Blast CellsMyeloid Neoplasia